Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6385633 | 0.84 | ATM (0.39) | CDK2CCNA2CCNA1CCNE1GLS | |
| SCHEMBL6385638 | 0.84 | ATM (0.39) | CDK2CCNA2CCNA1CCNE1GLS | |
| SCHEMBL31516877 | 0.83 | CCNA2 (0.45) | CDK2CCNA2CCNA1NPC1RAB9A | |
| SCHEMBL1106976 | 0.83 | CCNA2 (0.40) | CDK2CCNA2CCNA1IGF1R | |
| SCHEMBL5867668 | 0.82 | ABL1 (0.43) | CDK2SMN1; SMN2 | |
| SCHEMBL5867511 | 0.81 | NLRP3 (0.47) | CDK2CCNA2CCNA1CCNE2CCNE1 | |
| SCHEMBL5867399 | 0.80 | SMN1; SMN2 (0.42) | CDK2CCNA2CCNA1GAARAB9A | |
| SCHEMBL5867451 | 0.78 | CCNA2 (0.49) | CDK2CCNA2CCNA1NPC1RAB9A | |
| SCHEMBL5597817 | 0.78 | MEN1 (0.43) | GAANPC1RAB9A | |
| SCHEMBL5867670 | 0.77 | CCNA2 (0.59) | CDK2CCNA2CCNA1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202733-B1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-10-05 | — | — | EP | claimed |
| EP-1202733-A4 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2003-05-14 | — | — | EP | claimed |
| JP-2003507329-A | — | — | 2003-02-25 | — | — | JP | claimed |
| EP-1202733-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | claimed |
| US-6218418-B1 | THERAPY OF CELL PROLIFERATIVE DISORDERS ASSOCIATED WITH AN ALTERED CELL DEPENDENT KINASE ACTIVITY BY ADMINISTERING AMINO PYRAZOLE DERIVATIVE TO MAMMAL | PHARMACIA & UPJOHN S.P.A (IT) | 2001-04-17 | — | — | US | claimed |
| WO-2001012189-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-02-22 | — | — | WO | claimed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-7034049-B1 | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2006-04-25 | — | — | US | disclosed |
| EP-1202733-B1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-10-05 | — | — | EP | disclosed |
| CN-1649848-A | Fused pyrimidines derivatives as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LTD (GB) | 2005-08-03 | — | — | CN | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| CN-1454091-A | Immunostimulatory nucleic acids | UNIV IOWA RES FOUND (US) | 2003-11-05 | — | — | CN | disclosed |
| EP-1202733-A4 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| CN-1373662-A | 3(5)-amino-pyrazole derivs., process for their preparation and their use as antitumor agents | PHARMACIA & UP JOHN S P A (IT) | 2002-10-09 | — | — | CN | disclosed |
| EP-1202733-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | disclosed |
| US-6218418-B1 | THERAPY OF CELL PROLIFERATIVE DISORDERS ASSOCIATED WITH AN ALTERED CELL DEPENDENT KINASE ACTIVITY BY ADMINISTERING AMINO PYRAZOLE DERIVATIVE TO MAMMAL | PHARMACIA & UPJOHN S.P.A (IT) | 2001-04-17 | — | — | US | disclosed |
| WO-2001012189-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | CDK2 273/4885CCNA2 408/4885CCNA1 642/4885 |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | CDK2 421/4885CCNA2 1329/4885CCNA1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.